The company has completed a Phase I investigator-initiated clinical trial of ‘MIRX002’ targeting malignant pleural mesothelioma, achieving safety and primary endpoints. Future plans include advancing overseas clinical development.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7777","jir_company_name":"Three-Dee Matrix Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/7777-20260608-01.pdf","jir_short_summary":"The company has completed a Phase I investigator-initiated clinical trial of 'MIRX002' targeting malignant pleural mesothelioma, achieving safety and primary endpoints. Future plans include advancing overseas clinical development.","jir_summary":"### Performance Overview\nThis document reports that the company has completed a Phase I investigator-initiated clinical trial of 'MIRX002' targeting malignant pleural mesothelioma, achieving safety and primary endpoints. The trial confirmed safety in both single and repeated dosing tests, with no adverse effects observed, demonstrating safe administration up to three times. This progress advances preparations for overseas clinical development and represents a significant milestone for future business expansion.\n\n### Future Outlook and Corporate Activities\nThe company will continue development in collaboration with PURMX Corporation. The trial results accelerate overseas clinical development for this drug, which has received orphan drug designation in the United States. The direct impact on future business development and revenue remains unknown at this stage. This progress is also positioned as an important milestone in the company's medium-term management plan.","jir_financial_highlights":"Clinical trial completion: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Three-DeeMatrix, #PharmaceuticalDevelopment, #JapanStocks","jir_key_figures":"Clinical trial completion: Unknown\nSafety and tolerability assessment: Primary endpoints achieved\nOverseas clinical development: Ongoing","jir_meta_title":"\u3010Three-Dee Matrix\u3011Malignant Pleural Mesothelioma Clinical Trial Completion\uff5cJune 2026","jir_meta_description":"Three-Dee Matrix has completed a clinical trial targeting malignant pleural mesothelioma, achieving safety and primary endpoints. Progressing towards overseas clinical development.","jir_og_title":"\u3010Three-Dee Matrix\u3011Trial Completion and Future Outlook\uff5cJune 2026","jir_og_description":"The company has completed the trial for malignant pleural mesothelioma and confirmed safety. Advancing overseas clinical development, expectations for future business expansion are high.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56804,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-62266","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n